The Purvalanol A (CDK Inhibitor) market has demonstrated impressive growth, expanding from $0.64 billion in 2025 to $0.7 ...

Dr Fatima Cardoso, director of the Breast Cancer Unit at Champalimaud Cancer Centre in Lisbon, Portugal, is a leader in a global initiative [2] to improve the care and treatment of persons with ...

As clinicians celebrated results of the PALOMA-2 study at ASCO Annual Meeting in 2016, Gabe S. Sonke, MD, PhD, had a question ...

Regor Pharma, a Shanghai-Boston biotech, sold global rights to Genentech for two early-stage CDK inhibitors aimed at breast cancer. Kailera Therapeutics launched with a four-drug pipeline aimed at the ...

(RTTNews) - Regor Pharmaceuticals USA has entered into a definitive purchase agreement, under which Genentech, a member of the Roche Group, will acquire a portfolio of next-generation CDK inhibitors ...

CDK 4/6 inhibitors (CDK4/6i) remain part of the standard first-line treatment for patients with hormone receptor–positive metastatic breast cancer, offering demonstrable improvements in both ...

Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. The current PI3K 3C inhibitors in use in ...